Patents by Inventor Subramanian Karur

Subramanian Karur has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused indazole pyridone compounds as antivirals
    Patent number: 10975078
    Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: April 13, 2021
    Assignee: NOVARTIS AG
    Inventors: Jiping Fu, Wooseok Han, Subramanian Karur, Peichao Lu, Keith Bruce Pfister, Joseph Michael Young
  • FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS
    Publication number: 20200270252
    Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.
    Type: Application
    Filed: March 4, 2020
    Publication date: August 27, 2020
    Inventors: Jiping FU, Wooseok HAN, Subramanian KARUR, Peichao LU, Keith Bruce PFISTER, Joseph Michael YOUNG
  • FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS
    Publication number: 20190300530
    Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.
    Type: Application
    Filed: April 12, 2019
    Publication date: October 3, 2019
    Inventors: Jiping FU, Wooseok HAN, Subramanian KARUR, Peichao LU, Keith Bruce PFISTER, Joseph Michael YOUNG
  • Fused indazole pyridone compounds as antivirals
    Patent number: 10301312
    Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: May 28, 2019
    Assignee: Novartis AG
    Inventors: Jiping Fu, Wooseok Han, Subramanian Karur, Peichao Lu, Keith Bruce Pfister, Joseph Michael Young
  • FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS
    Publication number: 20180312507
    Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.
    Type: Application
    Filed: April 27, 2018
    Publication date: November 1, 2018
    Inventors: Jiping FU, Wooseok HAN, Subramanian KARUR, Peichao LU, Keith Bruce PFISTER, Joseph Michael YOUNG
  • Isoxazole hydroxamic acid compounds as LpxC inhibitors
    Patent number: 10029994
    Abstract: This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: July 24, 2018
    Assignee: Novartis AG
    Inventors: Jiping Fu, Xianming Jin, Subramanian Karur, Guillaume Lapointe, Ann Marie Madera, Zachary Kevin Sweeney
  • ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS
    Publication number: 20180030004
    Abstract: This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.
    Type: Application
    Filed: October 9, 2017
    Publication date: February 1, 2018
    Inventors: Jiping FU, Xianming JIN, Subramanian KARUR, Guillaume LAPOINTE, Ann Marie MADERA, Zachary Kevin SWEENEY
  • Isoxazole hydroxamic acid compounds as LpxC inhibitors
    Patent number: 9815804
    Abstract: This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: November 14, 2017
    Assignee: Novartis AG
    Inventors: Jiping Fu, Xianming Jin, Subramanian Karur, Guillaume Lapointe, Ann Marie Madera, Zachary Kevin Sweeney
  • Isoxazoline hydroxamic acid derivatives as LpxC inhibitors
    Patent number: 9718792
    Abstract: This invention pertains generally to compounds of Formula I and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention pertains to methods and compositions for treating infections caused by Gram-negative bacteria.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: August 1, 2017
    Assignee: Novartis AG
    Inventors: Jiping Fu, Xianming Jin, Subramanian Karur, Guillaume LaPointe, Patrick Lee, Zachary Kevin Sweeney
  • ISOXAZOLINE HYDROXAMIC ACID DERIVATIVES AS LpxC INHIBITORS
    Publication number: 20170174640
    Abstract: This invention pertains generally to compounds of Formula I and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention pertains to methods and compositions for treating infections caused by Gram-negative bacteria.
    Type: Application
    Filed: March 9, 2017
    Publication date: June 22, 2017
    Inventors: Jiping FU, Xianming JIN, Subramanian KARUR, Guillaume LAPOINTE, Patrick LEE, Zachary Kevin SWEENEY
  • Isoxazoline hydroxamic acid derivatives as LpxC inhibitors
    Patent number: 9637482
    Abstract: This invention pertains generally to compounds of Formula I and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention pertains to methods and compositions for treating infections caused by Gram-negative bacteria.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: May 2, 2017
    Assignee: Novartis AG
    Inventors: Jiping Fu, Xianming Jin, Subramanian Karur, Guillaume Lapointe, Patrick Lee, Zachary Kevin Sweeney
  • ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS
    Publication number: 20170088525
    Abstract: This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.
    Type: Application
    Filed: December 12, 2016
    Publication date: March 30, 2017
    Inventors: Jiping FU, Xianming JIN, Subramanian KARUR, Guillaume LAPOINTE, Ann Marie MADERA, Zachary Kevin SWEENEY
  • Cyclic peptides and use as medicines
    Patent number: 9566312
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, and A-B are as defined herein, which are non-immunosuppressive, cyclophilin-binding, mPTP blockers and are therefore useful for the prevention or treatment of diseases or disorders such as HCV infection, stroke, multiple sclerosis, HBV infection, HPV infection, asthma, cancer, muscular dystrophy, sepsis, ischemia/reperfusion injury, and heart failure.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: February 14, 2017
    Assignee: Novartis AG
    Inventors: Jiping Fu, Subramanian Karur, Xiaolin Li, Peichao Lu, Wosenu Mergo, Alexey Rivkin, Zachary Kevin Sweeney, Meiliana Tjandra, Andrew Weiss, Aregahegn Yifru
  • ISOXAZOLINE HYDROXAMIC ACID DERIVATIVES AS LpxC INHIBITORS
    Publication number: 20170029415
    Abstract: This invention pertains generally to compounds of Formula I and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention pertains to methods and compositions for treating infections caused by Gram-negative bacteria.
    Type: Application
    Filed: April 22, 2015
    Publication date: February 2, 2017
    Applicant: Novartis AG
    Inventors: Jiping FU, Xianming JIN, Subramanian KARUR, Guillaume LAPOINTE, Patrick LEE, Zachary Kevin SWEENEY
  • Isoxazole hydroxamic acid compounds as LpxC inhibitors
    Patent number: 9549916
    Abstract: This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: January 24, 2017
    Assignee: Novartis AG
    Inventors: Jiping Fu, Xianming Jin, Subramanian Karur, Guillaume Lapointe, Ann Marie Madera, Zachary Kevin Sweeney
  • ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS
    Publication number: 20160166548
    Abstract: This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.
    Type: Application
    Filed: December 15, 2015
    Publication date: June 16, 2016
    Applicant: Novartis AG
    Inventors: Jiping FU, Xianming JIN, Subramanian KARUR, Guillaume LAPOINTE, Ann Marie MADERA, Zachary Kevin SWEENEY
  • CYCLIC PEPTIDES AND USE AS MEDICINES
    Publication number: 20150306172
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, and A-B are as defined herein, which are non-immunosuppressive, cyclophilin-binding, mPTP blockers and are therefore useful for the prevention or treatment of diseases or disorders such as HCV infection, stroke, multiple sclerosis, HBV infection, HPV infection, asthma, cancer, muscular dystrophy, sepsis, ischemia/reperfusion injury, and heart failure.
    Type: Application
    Filed: May 20, 2015
    Publication date: October 29, 2015
    Applicant: NOVARTIS AG
    Inventors: Jiping Fu, Subramanian Karur, Xiaolin Li, Peichao Lu, Wosenu Mergo, Alexey Rivkin, Zachary Kevin Sweeney, Meiliana Tjandra, Andrew Weiss, Aregahegn Yifru
  • Cyclic peptides and use as medicines
    Patent number: 9072696
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R3, R4, R5, and A-B are defined herein, which are non-immunosuppresive, cyclophilin-binding, mPTP blockers and are therefore useful for the prevention or treatment of diseases or disorders such as HCV infection, stroke, multiple sclerosis, HBV infection, HPV infection, asthma, cancer, muscular dystrophy, sepsis, ischemia/reperfusion injury, and heart failure.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: July 7, 2015
    Assignee: Novartis AG
    Inventors: Jiping Fu, Subramanian Karur, Xiaolin Li, Peichao Lu, Wosenu Mergo, Alexey Rivkin, Zachary Kevin Sweeney, Meiliana Tjandra, Andrew Weiss, Aregahegn Yifru
  • CYCLIC PEPTIDES AND USE AS MEDICINES
    Publication number: 20140134132
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R3, R4, R5, and A-B are defined herein, which are non-immunosuppresive, cyclophilin-binding, mPTP blockers and are therefore useful for the prevention or treatment of diseases or disorders such as HCV infection, stroke, multiple sclerosis, HBV infection, HPV infection, asthma, cancer, muscular dystrophy, sepsis, ischemia/reperfusion injury, and heart failure.
    Type: Application
    Filed: September 26, 2013
    Publication date: May 15, 2014
    Applicant: NOVARTIS AG
    Inventors: Jiping Fu, Subramanian Karur, Xiaolin Li, Peichao Lu, Wosenu Mergo, Alexey Rivkin, Zachary Kevin Sweeney, Meiliana Tjandra, Andrew Weiss, Aregahegn Yifru
  • Organic compounds and their uses
    Patent number: 8222425
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: July 17, 2012
    Assignee: Novartis AG
    Inventors: Shawn D. Britt, Lech Andrzej Ciszewski, Jiping Fu, Subramanian Karur, Yugang Liu, Peichao Lu, David Thomas Parker, Mahavir Prashad, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Aregahegn Yifru, Rui Zheng